There is an expanding role for bispecific antibodies in the treatment of lung cancer, with amivantamab (EGFR-MET–bispecific antibody) approved for the treatment of advanced EGFR-mutated NSCLC.101. This evidence concerns the gene EGFR and lung cancer.